Related Experiment Video
Updated: Jun 7, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Unveiling the Promise: Navigating Clinical Trials 1978-2024 for PDAC
Angel A Dominguez1, Matthew T Perz1, Yi Xu1
1Department of Cell Systems & Anatomy; University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Abstract:
Despite many decades of research, pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to diagnose and treat effectively. Although there have been improvements in the 5-year overall survival rate, it is still very low at 12.5%. The limited efficacy of current therapies, even when PDAC is detected early, underscores the aggressive nature of the disease and the urgent need for more effective treatments. Clinical management of PDAC still relies heavily on a limited repertoire of therapeutic interventions, highlighting a significant gap between research efforts and available treatments. Over 4300 clinical trials have been or are currently investigating different treatment modalities and diagnostic strategies for PDAC, including targeted therapies, immunotherapies, and precision medicine approaches. These trials aim to develop more effective treatments and improve early detection methods through advanced imaging techniques and blood-based biomarkers. This review seeks to categorize and analyze PDAC-related clinical trials across various dimensions to understand why so few chemotherapeutic options are available to patients despite the numerous trials being conducted. This review aims to provide a comprehensive and nuanced understanding of the landscape of PDAC-related clinical trials, with the overarching goal of identifying opportunities to accelerate progress in drug development and improve patient outcomes in the fight against this devastating disease.
Insights
Pancreatic cancer (PDAC) research has yielded over 4300 trials, yet effective treatments remain scarce. This review analyzes PDAC clinical trials to identify barriers and accelerate the development of novel therapies for this difficult cancer.
Area of Science:
- Oncology
- Clinical Trial Analysis
- Cancer Therapeutics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents significant diagnostic and therapeutic challenges, with a low 5-year survival rate of 12.5%.
- Current clinical management of PDAC relies on a limited range of interventions, despite extensive research efforts.
- The aggressive nature of PDAC necessitates the development of more effective treatment strategies.
Purpose of the Study:
- To categorize and analyze the vast landscape of over 4300 pancreatic ductal adenocarcinoma (PDAC) clinical trials.
- To understand the reasons behind the limited availability of chemotherapeutic options for PDAC patients.
- To identify opportunities for accelerating drug development and improving patient outcomes in PDAC.
Main Methods:
- Systematic review and categorization of PDAC-related clinical trials.
- Analysis of trial data across various dimensions, including treatment modalities and diagnostic strategies.
- Evaluation of targeted therapies, immunotherapies, and precision medicine approaches within clinical trials.
Main Results:
- Despite numerous clinical trials, a significant gap persists between research endeavors and available PDAC treatments.
- Analysis reveals potential reasons for the limited success in translating trial outcomes into approved therapies.
- Ongoing trials explore advanced imaging and biomarkers for improved early detection and treatment efficacy.
Conclusions:
- A comprehensive understanding of PDAC clinical trial trends is crucial for optimizing future research directions.
- Addressing the identified barriers can accelerate the development of novel and effective treatments for pancreatic cancer.
- Further investigation into trial design and therapeutic strategies is needed to improve patient survival rates for PDAC.
